BOSTON and SEOUL, Korea, June 6, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON" or "Company") announced today that the company has successfully completed the GLP toxicology studies of BAL200. The ...
Confirmed antibacterial efficacy against a variety of anthrax strains including the one used in the 2001 anthrax attack Provides the most potent bactericidal ability that no other PEP antibiotics in ...
BOSTON and SEOUL, South Korea, July 2, 2025 /PRNewswire/ -- More than 1,200 reported cases of CRE (Carbapenem-Resistant Enterobacteriaceae) infections have been reported in the In-cheon region of ...
SEOUL, South Korea and BOSTON, May 13, 2025 /PRNewswire/ -- iNtRON Biotechnology, Inc., a biotechnology company focused on developing innovative endolysin-based new biological drug for superbugs and ...
iNtRON Biotechnology, Inc. engages in the development of novel biopharmaceutical drugs in South Korea. It develops bacteriophage and endolysin based drugs through itLysin and IMPA platform. The ...
iNtRON stated that following the proprietary development of the Robot Bacteriophage 2 nd generation technology, additional in-vitro evolution technology was applied. The Company previously secured the ...
The MarketWatch News Department was not involved in the creation of this content. -- Gram-negative bacterial infections are becoming an increasingly serious global health issue -- U.S. patent ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results